Gilead Issues Statement On Zydelig U.S. Indication For Follicular Lymphoma And Small Lymphocytic Leukemia; Says Working With FDA To Complete Withdrawal Of FL, SLL Indications In U.S.
https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-zydelig-us-indication-for-follicular-lymphoma-and-small-lymphocytic-leukemia
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
10 Biggest Price Target Changes For Thursday
JP Morgan raised the price target for RPM International Inc. (NYSE: RPM) from $85 to $100. RPM shares rose 0.5% to $97.90 in pre-market trading.
Morgan Stanley Downgrades Gilead Sciences to Equal-Weight, Lowers Price Target to $74
Morgan Stanley analyst Matthew Harrison downgrades Gilead Sciences (NASDAQ:GILD) from Overweight to Equal-Weight and lowers the price target from $84 to $74.
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Here's a roundup of top developments in the biotech space over the last 24 hours.
Gilead’s Remdesivir Shows Consistent Efficacy In Patients With Comorbidities With Higher Risk for Severe COVID-19
Gilead Sciences Inc (NASDAQ: GILD)
Gilead on Tuesday Announced Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV pre-exposure prophylaxis (PrEP).
Gilead, Arcus Biosciences Complete Closing Of Option Exercise For 3 Clinical-Stage Programs And New Research Collaboration
Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced the closing of Gilead's option exercises to three programs in Arcus' clinical-stage portfolio and a new research